Despite being a successful and relatively safe antibiotic class, beta-lactams have not yet been included in TB-therapeutic regimens because of the inherent resistance of Mtb to this class, fundamentally attributed to a chromosomally encoded beta-lactamase, the impermeable nature of the mycobacterial CW and the predominance of non-classical PG cross-links, only efficiently inhibited by carbapenems (Cordillot et al., 2013; Wivagg et al., 2014; Story-Roller and Lamichhane, 2018). This evidence concerns the gene LACTB and tuberculosis.